Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Boots chain CEO Sebastian James quit as CEO after owner Walgreens Boots Alliance's plans for a 5 billion pound ($6.32 billion) sale or stock market listing of the company stalled, Sky News reporter Mark Kleinman said in a post on X on Saturday.

Boots CEO James quits after Walgreens' plans for sale stalls, Sky News reporter says

Akamai Technologies

Albemarle

Boeing

Charter Communications

CVS Health

Dayforce Inc

Dollar Tree

Estee Lauder

EPAM Systems

Etsy

Globe Life Inc

Global Payments

Intel

Lululemon Athletica

MarketAxess Holdings

Paramount Global

Paycom Software

Warner Bros Discovery Inc

The S&P 500 is up nearly 16% so far this year with dividends reinvested. Artificial intelligence has been the big theme driving gains for Big Tech, especially Nvidia Corp. But 38% of the S&P 500 have had negative returns during the first half of 2024.

These 20 stocks have been the S&P 500's biggest losers so far in 2024

Inflation Comes in as Expected

NIKE

Q2's expected quarterly earnings growth pace of +8.3% reflects the strongest growth since back in Q1 of 2022. Tech is expected to do some heavy lifting again, with earnings expected to be up +15.5% on +9.5% higher revenues.

Q2 Earnings Growth Forecasted to Hit Two-Year High

In the ever-changing world of stock markets, those looking for possible comeback tales sometimes find that cheap stocks provide fascinating chances. These stocks are industry heavyweights.

3 Beaten-Down Stocks Ready for a Comeback: June 2024

On Thursday, Walgreens Boots Alliance Inc (NASDAQ: WBA) reported third-quarter fiscal year 2024 sales of $36.35 billion, up 2.6% year over year (+2.5% on constant currency), beating the consensus of $36 billion.

Walgreens Boots Alliance Expected To Close 25% Of Stores, But Financial Benefit Visible Only Next Year-Analyst

NEW YORK, NY / ACCESSWIRE / June 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Walgreens Boots Alliance, Inc. ("Walgreens Boots Alliance, Inc.") (NASDAQ:WBA) concerning possible violations of federal securities laws. On June 27, 2024, following CEO Rosalind Brewer's abrupt resignation in September 2023, Walgreens announced 3Q24 financial results and reduced its revenue guidance for the fourth quarter and full fiscal year 2024.

Shareholder Rights Advocates at Levi & Korsinsky Investigate Walgreens Boots Alliance, Inc. (WBA) Regarding Possible Securities Fraud Violations

Walgreens Boots Alliance stock has declined over 83% from its all-time high, underperforming the S&P 500 and competitor CVS Health. The company reported mediocre third quarter results, but lowered full-year guidance once again. Although the stock seems extremely cheap, I would pass on an investment at this point.

Walgreens Boots Alliance: Maybe I Was Wrong

Walgreens Boots Alliance (WBA), which currently leads the S&P 500's worst-performing stocks in the first half of 2024, plummeted more than 22% to a 27-year low on Thursday after the pharmacy chain and healthcare provider missed profit estimates and slashed its outlook amid weakening consumer demand.

Watch These Levels in Walgreens' Stock Price After Plunge to 27-Year Low

Walgreens Boots Alliance NASDAQ: WBA is a global leader in integrated healthcare, pharmacy, and retail. The company recently released its earnings report for the third quarter of 2024, raising questions about its ability to navigate a challenging market environment and achieve sustainable growth.

Walgreens Stock Falls on Q3 Earnings Miss, Strategic Shifts Ahead

Shares in Walgreens Boots Alliance Inc (NASDAQ:WBA, ETR:W8A) tanked after hours in the wake of news the pharmacy chain plans to close a significant number of its US pharmacies due to mounting challenges in its retail business.  CEO Tim Wentworth indicated that the current pharmacy model is unsustainable, citing ongoing issues such as reduced reimbursement rates from pharmacy benefit managers.

Walgreens shares tank after CEO sounds the alarm over store closures

Amazon

CNBC's Jim Cramer told investors why he thinks Amazon is making it hard for Walgreens to succeed. Walgreens earnings fell short of Wall Street's expectations, and shares had plunged 22% by Thursday's close.

How is Amazon hurting Walgreens' business? Jim Cramer explains

Levi Strauss

Micron Technology

Micron Technology, Walgreens Boots Alliance and Levi's were three of Thursday's biggest movers.

Stock Market Today: Stocks End Higher Ahead of May PCE Data

Walgreens Boots Alliance reported slow sales growth of 2.6% and lowered full-year earnings guidance to $2.80 to $2.95 per share. The company expects to close stores to cut costs and improve profits.

Why Walgreens Boots Alliance Shares Plunged Today

Walgreens will be closing a substantial number of its more than 8,600 U.S. stores over the next three years.

Walgreens is closing a chunk of its 8,600 stores as the list of struggling retailers grows

Challenges in the retail environment and the pharmacy industry have led Walgreens Boots Alliance to consider closing as many as 25% of its U.S. retail stores.

Walgreens Considers Closing 25% of Stores Amid Consumer Price Sensitivity

Cencora Inc

Cencora stock and other drug distributors fell on Wednesday, hit by Walgreens results, not the ruling that killed an opioid settlement.

Drug Distributor Cencora Falls; Blame Walgreens, Not The Supreme Court

Walgreens Boots Alliance Inc (NASDAQ:WBA, ETR:W8A) shares plunged 25% on Thursday after the pharmacy giant lowered its full-year profit guidance, warned more US store closures are to come, and delivered fiscal third quarter earnings below estimates. For the full year, Walgreens now expects adjusted earnings per share (EPS) in the range of $2.80 to $2.95 from its prior forecast of $3.20 to $3.35 and below the $3.21 expected by analysts.

Walgreens Boots Alliance shares plunge on slashed profit guidance

Junk bonds issued by Walgreens Boots Alliance Inc. were among the biggest decliners in the high-yield market on Thursday, swept up in the downdraft of a stock that was trading at a 27-year low.

Walgreens' junk bonds among biggest decliners in high-yield market after earnings disappoint

Walgreens recently reported its Q3'24 results (fiscal ends in August), with revenue exceeding but earnings falling short of our expectations. The company reported revenue of $36.4 billion and adjusted earnings of $0.63 per share, compared to our estimates of $36 billion, and $0.75, respectively.

Down Over 50% This Year Should You Pick Walgreens Stock At $12?

Walgreens announced it will be cutting its profit forecast for the fiscal 2024 year and closing more stores across the US in its latest attempt to deal with a "difficult operating environment."

Walgreens could shutter over 2K stores as sales plunge amid stubborn inflation

Walgreens Boots Alliance, Inc. (NASDAQ:WBA ) Q3 2024 Earnings Conference Call June 27, 2024 8:30 AM ET Company Participants Tiffany Kanaga - VP of IR Tim Wentworth - CEO Manmohan Mahajan - Global Chief Financial Officer Mary Langowski - President, U.S. Healthcare Rick Gates - SVP and Walgreens Chief Pharmacy Officer Tracey Brown - President, Walgreens' Retail and Chief Customer Officer Conference Call Participants Lisa Gill - JPMorgan Charles Rhyee - TD Cowen Eric Percher - Nephron Research Ann Hynes - Mizuho Securities Kevin Caliendo - UBS Michael Cherny - Leerink Partners Elizabeth Anderson - Evercore ISI George Hill - Deutsche Bank Stephanie Davis - Barclays Operator Good day and thank you for standing by. Welcome to the Walgreens Boots Alliance Third Quarter 2024 Results Conference Call.

Walgreens Boots Alliance, Inc. (WBA) Q3 2024 Earnings Call Transcript

Walgreens (NASDAQ: WBA ) stores will be closing as the company's CEO announces that “imminent” changes need to happen at the struggling pharmacy chain. According to CEO Tim Wentworth, Walgreens has continued to have trouble courting customers as they are resistant to current prices.

Walgreens Stores Closing: Retailer Announces ‘Imminent' Changes as WBA Stock Slumps

Drugstore chain is closing underperforming stores as it struggles with a weak consumer, pressure on pharmacy margins.

Walgreens Boots Alliance's stock headed for 27-year low after profit miss and lowered guidance

Walgreens Boots Alliance (WBA) shares crashed to their lowest level since 1997 on Thursday as the big pharmacy chain and healthcare provider missed profit estimates, slashed guidance, and planned major location closings because of weak consumer demand.

News for Walgreens Stock (WBA)